businesspress24.com - Ingen Receives Favorable Analyst Report
 

Ingen Receives Favorable Analyst Report

ID: 1172281

(firmenpresse) - RIVERSIDE, CA -- (Marketwire) -- 11/16/12 -- Ingen Technologies, Inc. (PINKSHEETS: IGNT), an emerging medical device manufacturer with patented proprietary technology for the growing $4 billion Respiratory Market, is pleased to announce that it will release an Analyst Research Report on December 3, 2012. The in-depth report forecasts the Company's revenues to grow to $2.0 million in FY-2013 and $50.0 million by 2018. Based on an average of the Cohen Price Target, IGNT common stock is valued at $0.15 per share, 1,878.1% higher than the current market price of $0.0075 per share. According to the report IGNT is an interesting short term trade and potentially a long term investment.

According to this report, the market potential for the Company's products is estimated to be around $200 million annually. Ingen, with its innovative products, is well positioned to capitalize on the growing market opportunity, driven by the growing aging population and the increase in home healthcare services.

In addition, the 828 companies in the high-tech medical device industry generate in excess of $60 billion in revenue and employ over 88,000 workers. Medtronic, GE and St. Jude Medical are the top three grossing companies, controlling 31.9% of market share. Ingen is positioning itself to be a global player in the growing industry. Since Oxyview is the only pneumatic flow meter using gravity-independent technology, Ingen is in a strong position to compete with gravity-dependent technologies currently available in the market.

Further, with sales through the National Distributor, we expect Ingen to aggressively explore various opportunities with government-based medical equipment suppliers that would provide Oxyview® to VA Hospitals and Department of Defense military medical facilities. The Company has already received a GSA-Department of Veterans Affairs Federal Supply Contract Award that will allow Ingen to explore this segment. Ingen plans to deliver product to GSA facilities in 2013.





VISIT OUR WEBSITE AT: or FACT SHEET AT:

This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.



Contact:
Gary Tilden
951-688-7840


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  EnWave's 3rd Tier 1 Collaborator Enters into Market Evaluation Following Successful R&D Phase
EnteroMedics to Present at Canaccord Genuity 2012 Medical Technology and Diagnostic Forum
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 16.11.2012 - 12:18 Uhr
Sprache: Deutsch
News-ID 1172281
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

RIVERSIDE, CA


Phone:

Kategorie:

Alternative


Anmerkungen:


Diese Pressemitteilung wurde bisher 157 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ingen Receives Favorable Analyst Report
"
steht unter der journalistisch-redaktionellen Verantwortung von

Ingen Technologies, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Ingen Technologies, Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 68


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.